Nuntius Therapeutics GTM brain

category

market profile

• text: Targeted delivery and scalable manufacturing are major hurdles for nucleic acid medicines.
• text: Nuntius is developing mRNA and gene editing therapies while partnering with pharma on cancer immunotherapy delivery.

personas

• title: Head of RNA therapeutics research
  pains:

  • Delivering payloads selectively to the desired cell population
  • Moving beyond delivery concentrated in the liver
• title: Biopharma business development leader
  pains:

  • Finding differentiated delivery platforms compatible with a therapeutic program
  • Assessing preclinical evidence and partnership rights

icp

• text: Pharmaceutical companies developing mRNA cancer immunotherapies, exemplified by the announced Taiho collaboration.
• text: Biotechnology companies pursuing gene editing or RNA programs needing cell-specific systemic delivery.

message pillars

• text: Cell-specific delivery is the core platform proposition.
• text: Materials are designed for systemic delivery at scale.
• text: High-throughput screening guides nanocarrier discovery.

objections

• objection: Does cell selectivity translate to our payload and disease?
  response: Review program-specific preclinical biodistribution, expression and safety data under a collaboration evaluation.
• objection: Can the technology be manufactured for clinical use?
  response: Request manufacturing, scale-up and quality evidence for the proposed nanocarrier rather than assuming clinical readiness.

competitors

• name: Arcturus Therapeutics
  why: Develops RNA medicines and lipid nanoparticle delivery technology.
• name: NanoVation Therapeutics
  why: Develops nanoparticle delivery approaches for genetic medicines.

keywords

• cell specific RNA delivery
• targeted mRNA nanocarriers
• gene editing delivery platform
• extrahepatic nucleic acid delivery
• cancer immunotherapy mRNA delivery

voice

• scientific
• ambitious
• technology-led

signals

• text: A pharma company announces an mRNA oncology program and needs targeted delivery.
• text: A biotech program needs delivery beyond existing lipid nanoparticle target tissues.

stack

• machine learning
• mRNA
• nanocarriers

pricing

motion

channels

• scientific publications
• biopharma partnerships
• industry press

confidence

Founders

• name: Benita Nagel
  title: Founder
  role: Founder
• name: Albert Kwok
  title: Founder
  role: Founder